skip to main content

H.R. 4812 (108th): Stem Cell Discovery Through Diversity Act

The text of the bill below is as of Jul 12, 2004 (Introduced).


HR 4812 IH

108th CONGRESS

2d Session

H. R. 4812

To require the National Institutes of Health to conduct and support research using human embryonic stem cells, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

July 12, 2004

Mr. DEUTSCH introduced the following bill; which was referred to the Committee on Energy and Commerce


A BILL

To require the National Institutes of Health to conduct and support research using human embryonic stem cells, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ‘Stem Cell Discovery Through Diversity Act’.

SEC. 2. STEM CELL RESEARCH; REQUIREMENT REGARDING RELATION TO INFERTILITY TREATMENT; DIVERSITY IN STEM CELLS.

    (a) In General- The Director of the National Institutes of Health (referred to in this Act as the ‘Director of NIH’), acting through the national research institutes, shall in accordance with this section conduct and support research using human embryonic stem cells.

    (b) Applicability of 2000 NIH Final Guidelines-

      (1) In general- The Director of NIH shall ensure that research under subsection (a) is conducted and supported in accordance with the final guidelines regarding such research that were issued by the National Institutes of Health and published in the Federal Register on August 25, 2000 (65 FR 51976 et seq.), including--

        (A) the requirement that human embryonic stem cells used in the research be derived from human embryos that were created in vitro for purposes of fertility treatment and were in excess of the clinical need of the individuals seeking such treatment;

        (B) the requirement that individuals seeking such treatment voluntarily donated such embryos through a process of informed consent; and

        (C) the prohibition that Federal funds may not be used for the derivation of such cells from the embryos.

      (2) Certain restrictions- Restrictions on research described in subsection (a) established for the Department of Health and Human Services pursuant to policies announced by the President on August 9, 2001, have no legal effect on or after the date of the enactment of this Act.

      (3) Additional administrative polices- With respect to research under subsection (a), Federal administrative policies in addition to the guidelines under paragraph (1) may not be established or applied.

    (c) Diversity in Sources of Stem Cells- With respect to donations referred to in subsection (b)(1)(B) (relating to sources of human embryonic stem cells), the Director of NIH shall ensure that the program under subsection (a) includes donations from a significant number of individuals who are members of racial or ethnic minority groups in order to make progress toward the goal (consistent with principles underlying the requirement under section 492B of the Public Health Service Act that such individuals be included as subjects in research) of developing an understanding of whether the variables studied in clinical research affect such individuals differently than the general population.

    (d) Report to Congress- The Director of NIH shall annually submit to the Congress a report on the program of research carried out under subsection (a). The report shall include a description of the actions taken by the Director to comply with subsection (c) and a determination by the Director of the progress being made toward the goal described in such subsection.

SEC. 3. RONALD REAGAN OFFICE OF HUMAN STEM CELL RESEARCH.

    The Director of NIH shall establish within the office of the Director an office to be known as the Ronald Reagan Office of Human Stem Cell Research, which shall be headed by a director appointed by the Director of NIH. The Office shall coordinate all research conducted or supported by the National Institutes of Health that uses human pluripotent stem cells.